HeartBeam, Inc.

HeartBeam maintains a fragile capital structure characterized by high liquidity risk and negative equity returns. The company holds $2.04 million in cash and equivalents against $3.29 million in total liabilities, resulting in a current ratio of 0.74, which indicates current liabilities exceed current assets. Total equity stands at $635,000, yielding a price-to-book ratio of 56.76 and a return on equity of -7.40. The firm generated an operating loss of $4.72 million and a net loss of $4.70 million in Q1 2026, with operating cash flow at -$3.61 million and free cash flow at -$3.86 million. The debt-to-equity ratio is 0.0, suggesting reliance on equity financing rather than debt, but the negative cash burn rate of approximately $3.86 million per quarter threatens solvency without immediate capital infusion.

Profitability metrics are deeply negative, reflecting the company's pre-revenue or early-stage commercialization status. The return on assets is -1.20, and the EV/EBITDA ratio is -7.21, indicating the market values the enterprise at a fraction of its negative earnings before interest, taxes, depreciation, and amortization. There are no positive operating margins, as operating income is -$4.72 million. The company incurs significant research and development and general and administrative expenses, including substantial stock-based compensation, which dilutes existing shareholders. The lack of profitability is consistent with early-stage medical device companies that have not yet achieved scale or regulatory clearance for widespread commercial sales.

Revenue concentration and segment data are not explicitly detailed in the financial snapshot, but the business model relies on the HeartBeam System and the upcoming extended-wear patch. The company’s geographic exposure is primarily domestic, with filings referencing California, Arizona, and New Jersey jurisdictions. The absence of diversified revenue streams means the company’s financial health is entirely dependent on the successful commercialization and adoption of its core ECG technology. Any delay in regulatory approval or market acceptance would directly impact the company’s ability to generate revenue and achieve profitability.

The growth trajectory is currently negative in terms of cash reserves and equity value. Cash and equivalents declined from $4.38 million at the end of 2025 to $2.04 million in Q1 2026, a decrease of over 50% in one quarter. Shares outstanding increased from 40.12 million to 41.13 million, indicating recent equity issuances. The company has incurred losses since inception, with negative cash flows from operations in every year. The recent financing activities, including proceeds from the sale of equity under an ATM program, have been necessary to sustain operations, but the burn rate suggests that existing cash reserves may not support more than one or two additional quarters of operations without further fundraising.

Risk factors are elevated, with high liquidity risk and medium dilution risk. The company’s filings reference going-concern or substantial-doubt language, highlighting the uncertainty of its ability to continue as a going concern. The current ratio of 0.74 and the negative cash flow position exacerbate this risk. Additionally, the company faces dilution risk from ongoing equity offerings, including an At-The-Market (ATM) offering program and public stock offerings. The recent issuance of shares and the presence of warrants and stock options further contribute to potential dilution for existing shareholders.

Recent events include the company’s stock price closing below $1.00 for 33 consecutive trading days, triggering a Nasdaq/NYSE minimum-bid deficiency threshold. This listing deficiency poses a significant risk of delisting if the company cannot regain compliance. Analyst estimates show a mean price target of $3.83, with a mean recommendation of 2.00 (buy), suggesting that analysts believe the current price is undervalued relative to the potential of the technology. However, the high severity of the listing deficiency and the company’s financial distress create a volatile investment environment.

Operating income -$4.7M.

• ▍Operating income -$4.7M

Operating income -$15.8M.

• ▍Operating income -$15.8M

Operating income -$10.5M.

• ▍Operating income -$10.5M

Operating income -$21.1M.

• ▍Operating income -$21.1M

Operating income -$19.9M.

• ▍Operating income -$19.9M

Operating income -$19.9M.

• ▍Operating income -$19.9M

Operating income -$15.3M.

• ▍Operating income -$15.3M

Operating income -$15.3M.

• ▍Operating income -$15.3M